Disclosed is a composition of matter involving a recombinant fusion protein comprising of a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.
本发明公开了一种物质组合物,涉及一种
重组融合蛋白,该蛋白由药理活性蛋白伴侣和来源于人类的小药理非活性蛋白结构域伴侣组成,例如但不限于第 10 个纤维粘连蛋白 III 结构域、SH3结构域、SH2结构域、IgG1的
CH2结构域、PDZ结构域、thrombospondin重复结构域、泛素结构域、富亮
氨酸重复结构域、绒毛顶端HP35结构域、绒毛顶端HP76结构域,或任何这些结构域的片段或修饰。还公开了编码融合蛋白的核酸(如DNA构建体)、表达载体和表达融合蛋白的
重组宿主细胞、含有
重组融合蛋白和药学上可接受的载体的药物组合物,以及生产具有药理活性的
重组融合蛋白的方法。